Related Experiment Video
Updated: Mar 14, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Adenosine Deaminase Activity in Chronic Lymphocytic Leukemia and Healthy Subjects
Bayazid Ghaderi1, Sabrieh Amini2, Farzad Maroofi2
1Department of Internal Medicine, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran.
Insights
Serum adenosine deaminase (ADA) shows high diagnostic value for B cell chronic lymphocytic leukemia (CLL). Elevated ADA levels correlate with CLL markers, suggesting its potential as a screening tool.
Area of Science:
- Hematology
- Oncology
- Biochemistry
Background:
- B cell chronic lymphocytic leukemia (CLL) is a prevalent hematologic malignancy.
- Current prognostic tools for CLL include CD markers and serum Beta-2-microglobulin (B2M).
Purpose of the Study:
- To evaluate serum adenosine deaminase (ADA) as a novel diagnostic marker for CLL.
- To assess the correlation of serum ADA activity with established CLL markers and disease staging.
Main Methods:
- Blood samples were analyzed from B-CLL patients and healthy controls.
- Serum ADA enzyme activity was measured alongside other hematologic parameters and biomarkers (B2M, LDH, ESR).
Main Results:
- Serum ADA activity was significantly elevated in CLL patients compared to controls.
- ADA showed significant positive correlations with B2M, white blood cell count (WBC), lactate dehydrogenase (LDH), and erythrocyte sedimentation rate (ESR).
- The diagnostic cut-off for serum ADA was 27.97 U/L, with 91% sensitivity and 94% specificity.
Conclusions:
- Elevated serum ADA activity is characteristic of CLL.
- Serum ADA demonstrates high diagnostic accuracy and may serve as a valuable screening tool for CLL.
- ADA's correlation with key CLL markers supports its utility in patient assessment.
Background:
B cell chronic lymphocytic leukemia is one of the most frequent hematologic malignancies in the world. Cellular surface CD markers and serum Beta-2-microglobulin may be used as a prognostic tool in CLL patients.
Objectives:
In the present study we introduce serum adenosine deaminase as a diagnostic marker in CLL.
Materials And Methods:
Blood samples were collected from B-CLL and healthy subjects. White blood cell, red blood cell and platelet count and blood Erythrocyte sedimentation rate was recorded and serum Beta-2-microglobulin, Lactate dehydrogenase and total ADA enzyme activity were determined.
Results:
Serum ADA activity was significantly higher in patients group than that of controls. ADA had a significant and direct correlation with B2M, WBC, LDH and ESR. However, there was not any relation between ADA and the stages of disease. Diagnostic cut-off, sensitivity and specificity of the serum ADA test were 27.97 U/L, 91% and 94%, respectively.
Conclusions:
A higher ADA activity in patients group and its correlation with CLL markers were seen in our study. High diagnostic value of serum ADA in our study suggests that it might be considered as a useful screening tool among the other markers in CLL.
